Trazodone

CHEMBL621 Phase 4 승인됨 Small molecule

Half-Life

5-9 hours

Bioavailability

—

Protein Binding

—

Molecular Weight

371.9 g/mol

LogP

2.8

Phase

4

Serotonin antagonism combined with reuptake inhibition places trazodone in the SARI category, distinct from the SSRIs in its receptor profile. It blocks serotonin receptors while inhibiting the serotonin transporter, with comparatively little action on other neurotransmitter systems, and it also engages the histamine H1 receptor. That antihistaminic component produces the sedation for which the drug is extensively used off-label in insomnia, alongside its approved role in depression. Unlike many hypnotics it is generally not habit-forming, a property that shapes prescribing preferences. A short elimination half-life of about five to nine hours accompanies its nervous-system classification. The molecule is C19H22ClN5O with a mass near 371.9 g/mol.

This antidepressant medication is prescribed for depression and is widely used off-label to treat insomnia because of its sedating properties. It works primarily by blocking serotonin receptors and inhibiting serotonin reuptake in the brain, with relatively little effect on other neurotransmitters. Unlike many sleep aids, it is generally not habit-forming.

분자량

371.8640 g/mol

LogP

2.80

TPSA

42.40 Å²

리핀스키 5의 법칙

통과

치료 영역

Psychiatry Insomnia HIV/AIDS Major Depressive Disorder

약물 분류

N — N - Nervous System

Pharmacokinetics (PK)

Half-Life 5-9 hours

Pharmacodynamics (PD)

2D 구조

SVG PNG

Cite this structure

Embed this structure

SMILES

O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12

InChI

InChI=1S/C19H22ClN5O/c20-16-5-3-6-17(15-16)23-13-11-22(12-14-23)8-4-10-25-19(26)24-9-2-1-7-18(24)21-25/h1-3,5-7,9,15H,4,8,10-14H2

Molecular Formula

C19H22ClN5O

HBD / HBA

- / 4

회전 가능 결합

5

무거운 원자

26

HRH1 (Histamine H1 Receptor) Antagonist

SLC6A4 (Serotonin Transporter) Inhibitor

Moderate Trazodone + Sertraline

Sertraline combined with trazodone may increase the risk of serotonin syndrome due to additive serotonergic effects.

Moderate Trazodone + Fluoxetine

Fluoxetine inhibits CYP2D6-mediated metabolism of trazodone, significantly increasing trazodone plasma levels and serotonin syndrome risk.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

This antidepressant medication is prescribed for depression and is widely used off-label to treat insomnia because of its sedating properties. It works primarily by blocking serotonin receptors and inhibiting serotonin reuptake in the brain, with relatively little effect on other neurotransmitters. Unlike many sleep aids, it is generally not habit-forming.

Key pharmacokinetic parameters for Trazodone: Half-life: 5-9 hours.

Yes, Trazodone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

Related Drugs

Same Drug Class

Acetaminophen Small molecule Aspirin Small molecule Sertraline Small molecule Escitalopram Small molecule

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL621. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5533. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

PillFYI

환자 친화적 정보를 찾고 계신가요?

Trazodone PillFYI에서

구조

핵심 데이터

Class: N - Nervous System
분자식: C19H22ClN5O
동의어: 2

외부 링크

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.